For example, expression of ERCC1 and XPA, components of the nucleotide excision repair pathways, are associated with platinum resistance in ovarian cancer (Damia et al, 1998; Selvakumaran et al, 2003); methylation and silencing of the mismatch repair gene MLH1 in some ovarian cancers also result in loss of cisplatin sensitivity (Strathdee et al, 1999); and disruption of the FANC/BRCA pathway by methylation of BRCA1 and FANCF alters sensitivity to cisplatin in ovarian cancer (Taniguchi et al, 2003). This evidence concerns the gene ERCC1 and ovarian carcinoma.